RaQualia Pharma Inc. provided consolidated earnings guidance for the year ending December 31, 2022. For the year, the company expected net sales of JPY 2,605 million, operating income of JPY 420 million, net income attributable to owners of parent of JPY 342 million or JPY 16.34 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
599 JPY | -0.83% | -1.64% | -12.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.94% | 82.93M | |
+29.69% | 699B | |
+25.07% | 571B | |
-4.76% | 364B | |
+17.69% | 326B | |
+3.51% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.68% | 154B |
- Stock Market
- Equities
- 4579 Stock
- News RaQualia Pharma Inc.
- RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022